Biopharmaceutical company developing drugs for neurological disorders.

The $US156 billion real estate fund manager says the growing disparity between new and old office assets creates scope for profit – once values have fallen enough.

TCS posted a 1.7% year-on-year drop in consolidated net profit to Rs 12,224 crore for the quarter ending March 2025, down from Rs 12,434 crore in the same period last year. The result came in below ...